Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial

Lancet

Volumn 354, Issue 9195, 1999, Pages 2019-2024

  Topol, Eric J ^a   Mark, Daniel B ^b   Lincoff, A Michael ^a   Cohen, Eric ^c   Burton, Jeffrey ^d   Kleiman, Neal ^e   Talley, David ^f   Sapp, Shelly ^a   Booth, Joan ^a   Cabot, Catherine F ^g   Anderson, Keaven M ^g   Califf, Robert M ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^g CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; HEPARIN; INSULIN; PLACEBO; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD VESSEL OCCLUSION; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RISK FACTOR; STATISTICAL MODEL; STENOSIS; SURVIVAL RATE; UNITED STATES;

EID: 0033547597     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)10018-7     Document Type: Article

References (35)

1. Topol E.J. Coronary-artery stents-gauging, gorging, and gouging. N Engl J Med. 339:1998;1702-1704.
2. Serruys P.W., de Jaegere P., Kiemeneij F.et al. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
3. Fischman D.L., Leon M.B., Baim D.S.et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 331:1994;496-501.
4. Serruys P.W., van Hout B., Bonnier H.et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II). Lancet. 352:1998;673-681.
5. Schömig A., Neumann F.J., Kastrati A.et al. A randomized comparison of anti platelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 334:1996;1084-1089.
6. Leon M.B., Baim D.S., Popma J.J.et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 339:1998;1665-1671.
7. Hall P., Nakamura S., Maiello L.et al. Arandomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 93:1996;215-222.
8. Bertrand M.E., Legrand V., Boland J.et al. Randomized multicenter comparison of conventional anticoagulation versus anti-platelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 98:1998;1597-1603.
9. Urban P., Macaya C., Rupprecht H.J.et al. Randomized evaluation of anticoagulation versus anti-platelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 98:1998;2126-2132.
10. Mak K.H., Belli G., Ellis S.G., Moliterno D.J. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol. 27:1996;494-503.
11. Farb A., Sangiorgi G., Carter A.J.et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 99:1999;44-52.
12. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 352:1998;87-92.
13. Lincoff A.M., Califf R.M., Moliterno D.J.et al. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 341:1999;319-327.
14. Mark D.B. Medical economics for interventional cardiology. Topol E.J. Textbook of interventional cardiology. 1999;889-909 WB Saunders, Philadelphia.
15. Mark D.B., Talley J.D., Topol E.J.et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary angioplasty. Circulation. 94:1996;629-635.
16. Mark D.B., Harrington R.A., Lincoff A.M.et al. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes. Circulation. 1999;. (in press).
17. Mark D.B., Hlatky M.A., Califf R.M.et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 332:1995;1418-1424.
18. Mark D.B., Lam L.C., Lee K.L.et al. Effects of coronary angioplasty, coronary bypass surgery, and medical therapy on employment in patients with coronary artery disease: a prospective comparison study. Ann Intern Med. 120:1994;111-117.
19. Lincoff A.M., Mark D.B., Califf R.M.et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG trial. J Am Coll Cardiol. 29:1997;240. (abstr).
20. Topol E.J., Leya F., Pinkerton C.A.et al. A comparison of coronary angioplasty with directional atherectomy in patients with coronary artery disease. N Engl J Med. 329:1993;221-227.
21. Miller J.M., Ohman E.M., Moliterno D.J., Califf R.M. Restenosis: the clinical issues. Topol E.J. Textbook of interventional cardiology, 3rd edn. 1999;379-415 WB Saunders, Philadelphia.
22. Topol E.J., Ferguson J.J., Weisman H.F.et al. Long term protection from myocardial ischemic events after brief integrin β3 blockade with percutaneous coronary intervention. JAMA. 278:1997;479-484.
23. Randomised placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: the CAPTURE study. Lancet. 349:1997;1429-1435.
24. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
25. Brener S.J., Barr L.A., Burchenal J.E.B.et al. A randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 98:1998;734-741.
26. Neumann F.J., Blasini R., Schmitt C.et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 98:1998;2695-2701.
27. Ellis S.G., Serruys P.W., Popma J.J.et al. Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. Circulation. 96:1997;1-87. (abstr) (suppl I).
28. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 335:1996;217-225.
29. Abdelmeguid A.E., Whitlow P.L., Sapp S.K., Ellis S.G., Topol E.J. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation. 91:1995;2733-2741.
30. Abdelmeguid A.E., Topol E.J., Whitlow P.L., Sapp S.K., Ellis S.G. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 94:1996;1528-1536.
31. Simoons M.L., van den Brand M., Lincoff A.M.et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J. 20:1999;1112-1119.
32. Kong T.Q. Jr., Davidson C.J., Meyers S.N., Tauke J.T., Parker M.A., Bono R.O. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 277:1997;461-466.
33. Ohman E.M., Tardiff B.E. Peri-procedural cardiac marker elevation after percutaneous coronary artery revascularization: importance and implications. JAMA. 277:1997;495-497.
34. Adgey A.A.J., Mathew T.P., Harbinson M.T. Peri-procedural creatine kinase-MB elevations: long-term impact and clinical implications. Clin Cardiol. 22:1999;257-265.
35. Mark D.B., Hlatky M.A., Califf R.M.et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 332:1995;1418-1424.